Practice Area

Ms. Wang's primary practice domains encompass life science, M&A, VC and PE investments, cross-border investments, as well as regulatory compliance. Ms. Wang possesses extensive expertise in the realm of corporate business and transactions. She has represented numerous Fortune 500 companies, PE funds, major state-owned groups, and private enterprises in various types of transactions such as control acquisition, pre-IPO equity investment, formation and exit of joint ventures, asset sales and licensing transactions, as well as overseas listing. She excels at providing clients with legal services of commercial value through acute business thinking and communication skills.

Boasting rich experience in the medical industry, Ms. Wang has offered comprehensive legal services to many multinational pharmaceutical companies, local biotech and medical device companies regarding their R&D, clinical trials, product launch, commercialization, MAH transfer, licensing in/out, ODM/OEM production, compliance and entrance into overseas markets. Additionally, Ms. Wang's interests cover semiconductors, new energy, industrial manufacturing, real estate, education, and consumption.

The principal clients served by Ms. Wang include BMS, Fresenius, Johnson & Johnson, Philips, Fosun Group, Wuxi Apptec, XtaiPi, Ustar, Goldman Sachs, Carlyle, Temasek, CICC Capital, Hillhouse Capital, CBC Group, CPE, Alibaba, etc.

Representative Cases

Represented the consortium consisting of Centurium Capital, CPE, Temasek and Hillhouse Capital in the privatization of CBPO Biological, with a transaction value exceeding 4.76 billion US dollars (This transaction was selected as the Deal of the Year 2022 by IFLR)

Represented the consortium composed of Primavera Capital, CBC Group and Shanghai Pharma in the bidding for the ownership of a multinational pharmaceutical company's China business. The transaction simultaneously involved equity transfer, MAH transfer and localization of the production of imported drugs

Represented BMS in transferring MAH of a drug to Merck and continuation of providing OEM of the drug for Merck

Represented Fresenius in acquiring or establishing multiple hospitals across the country and provided long-term legal services for the renovation or operation of these hospitals after acquisition or establishment

Provided legal services regarding PRC law related regulatory issues for CBC Group’s acquisition of Hugel Inc., the largest medical beauty product company in South Korea

Represented Peet’s Coffee in entering the Chinese market and setting up its first flagship store nationwide

Represented Victrex in establishing a joint venture with local Chinese supplier and provided legal services for the construction of a new factory for the joint venture in China (including land acquisition, factory construction, government subsidy negotiations, raw material supply arrangement, etc.)

Represented an Israeli company listed on Nasdaq in selling its equity in a Chinese automotive joint venture with transaction amount exceeding 1.56 billion RMB

Represented the Chinese subsidiary of a shipping company headquartered in Israel in receiving strategic investment from Alibaba and establishing a long-term strategic partnership with Alibaba

Represented WuXi AppTec in making a strategic investment in an insurance technology company and assisted the client in establishing a joint venture dedicated to innovative medical insurance business with the target company

Supported three overseas insurance companies controlled by Fosun Group in establishing an investment platform to acquire ten medical property asset packages located across five states of the United States (with a transaction amount exceeding 200 million US dollars), and successfully completed the CFIUS review

Supported Fosun Group in acquiring an internationally renowned medical resort hotel located in Switzerland (including drug, health care product and cosmetic product lines and clinic diagnosis and treatment services), where the transaction involved asset reorganization and 100% equity acquisition

Represented Goldman Sachs Group, Carlyle Group and Temasek Group in financial or strategic investments in multiple domestic companies, covering industries such as new energy, real estate, education and manufacturing, etc.

Education Background

Ms. Wang obtained her Bachelor of Science degree from the School of Pharmaceutical Science at Zhejiang University. She received her Juris. Master degree (Chinese Law) and Juris. Doctor degree (US Law) from the School of Transnational Law at Peking University. Additionally, Ms. Wang is a member of LawWithoutWalls.

Working Experience

Ms. Wang joined T&C Law Firm in 2024. Before that, she practiced law for years at Fangda Partners and Jun He Law Firm. Additionally, she also served as legal counsel for Fosun Group and Bristol-Myers Squibb.